Loading…
← CockpitCompetitor Analysis › 317450.KS Myung in Pharm Co., Ltd.Open in the cockpit ↗

Myung in Pharm Co., Ltd.317450.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Other
Momentum strong 72
Mkt cap
$466M
US dollars, full cap
Free float
26%
of shares outstanding
$/day
$353,942
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+12.8 pp
WACC 5.6%
Hurdle
n/a
no reverse DCF
Close · KRW₩42,100
1D0.0%
1W-0.2%
1M+1.2%
3M-11.7%
6M-20.0%
YTD-38.9%
1Y-42.2%
ATR %2.8%
52w lowhigh49.1% off high

What Myung in Pharm does

Employees: 532

Myung in Pharm at a glance

Size Myung in Pharm (317450.KS) is a South Korea Health Care company (Pharmaceuticals: Other) with a market value of $466M, the 357th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩42,100 on 18 Nov 2026.

Performance Over six months the shares fell 20.0%, against -22.3% for the median peer and -37.2% for the South Korea market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 6.6% over the last twelve months (peer median -4.0%); the operating margin is 34.8% (peer median 8.5%).

Valuation It trades at 0.7× enterprise value to sales against a peer median of 2.9× (2nd cheapest of 20).

Capital Return on invested capital runs 12.8 points above its cost of capital (5.6% WACC).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026317450.KS 82Peer median 78
Six months, rebased to 100: Myung in Pharm against the median of its 20 peers (local-currency closes).

Myung in Pharm financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩297B₩287B₩269B₩242B₩226B
Revenue growth—+7%+11%+7%—
Gross profit₩192B₩179B₩173B₩157B₩147B
EBITDA₩114B₩103B₩105B₩95.1B₩87.2B
Net income₩91.5B₩81.4B₩68.7B₩74.5B₩57.4B
Free cash flow₩28.2B₩51.5B₩72.8B₩71.4B₩57.6B
Capital expenditure₩53.2B₩34.8B₩10.2B₩4.65B₩3.40B
Total debt₩677M₩1.39B₩2.70B₩3.89B₩4.95B

Quarterly statements and history in the cockpit →

Myung in Pharm competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-30%-20%-10%0%-20%0%603669002412002826002644AVBP301507BOI3002610775778017070025623005196004883007912877317450.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Myung in Pharm is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×2.5×5×7.5×603669002412002826002644301507BOI30026107751707300158002562300519300039600488603102300791317450.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Myung in Pharm is the large dot.

Myung in Pharm competitors and peer comparison

How Myung in Pharm compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Myung in Pharm against its 20 peers (data as of 18 Nov 2026)
Measure317450.KSPeer medianRank in peer set
1-month return+1.2%-11.4%3rd highest of 21
6-month return-20.0%-22.3%9th highest of 21
Distance from 52-week high-49.1%-41.8%7th lowest of 21
Revenue growth (TTM)+6.6%-4.0%5th highest of 19
Operating margin34.8%8.5%highest of 21
EV / Sales0.7×2.9×2nd cheapest of 20
ROIC minus cost of capital+12.8 pp-0.1 pp6th highest of 20
EV / EBITDA1.8×5.2×cheapest of 5
Net debt / EBITDA-3.7×-1.3×3rd least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Myung in Pharm 317450.KSSouth Korea$466M-20%+7%35%0.7×n/an/a
Lionco Pharmaceutical 603669.SSChina$474M+4%-6%-17%8.4×n/an/a
Hunan Hansen Pharmaceutical 002412.SZChina$532M-2%-4%21%3.0×1.4%+7.0%
Tibet Aim Pharm 002826.SZChina$407M-22%+13%14%2.9×0.4%+1.0%
Lanzhou Foci Pharmaceutical 002644.SZChina$548M-9%+6%6%3.3×15.4%+6.5%
ArriVent BioPharma AVBPUnited States$564M-60%n/a-3,620%34.2×n/an/a
Hangzhou Minsheng Healthcare 301507.SZChina$583M-23%+21%11%3.8×19.1%+12.1%
Boiron BOI.PAFrance$367M-31%-2%5%0.6×-0.8%-0.5%
ABA Chemicals 300261.SZChina$592M-26%-16%-23%4.9×n/an/a
CK Life Sciences International (Holdings) 0775.HKHong Kong$613M-30%0%0%2.0×n/an/a
Daiken Biomedical 7780.TWTaiwan$342M-19%n/a18%3.0×-1.6%n/a
Grape King Bio 1707.TWTaiwan$342M-27%-5%19%1.0×-17.2%+2.3%
Shanxi Zhendong Pharmaceutical 300158.SZChina$641M-22%-28%-25%1.8×n/an/a
Brother Enterprises 002562.SZChina$668M-33%+8%4%1.5×4.0%+13.5%
Zhejiang Xinguang Pharmaceutical 300519.SZChina$319M-15%+5%27%5.1×3.1%-1.3%
TCI 8436.TWOTaiwan$312M-24%-4%18%1.3×-12.1%-3.2%
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%3.4×0.4%+4.8%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%2.2×2.1%-1.3%
Weihai Baihe Biology Technological 603102.SSChina$296M-22%+18%14%0.9×-11.8%+9.6%
Sirio Pharma 300791.SZChina$759M-6%-9%1%1.5×14.1%+15.6%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%n/an/an/a

Questions

Which companies are Myung in Pharm's closest peers?
The cockpit's peer set: Lionco Pharmaceutical (603669.SS), Hunan Hansen Pharmaceutical (002412.SZ), Tibet Aim Pharm (002826.SZ), Lanzhou Foci Pharmaceutical (002644.SZ), ArriVent BioPharma (AVBP), Hangzhou Minsheng Healthcare (301507.SZ), Boiron (BOI.PA), ABA Chemicals (300261.SZ).
Is Myung in Pharm expensive compared with its peers?
On ev / sales it trades at 0.7× against a peer median of 2.9×, 2nd cheapest of 20 in its peer set.
How has Myung in Pharm stock performed?
Over six months to 18 Nov 2026 the shares returned -20.0% against -22.3% for the median peer; over one year -42.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.